Maryam Tabarzad | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Maryam Tabarzad | Pharmaceutical Science | Best Researcher Award

Assist Prof Dr Maryam Tabarzad, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Iran

Based on Dr. Maryam Tabarzad’s profile, she appears to be a strong candidate for the Best Researcher Award due to several key factors:

Publication profile

google scholar

Educational Background

  • MSc in E-learning in Medical Education (2023): Focused on enhancing lab skills through augmented reality in pharmacy students.
  • PhD in Pharmaceutical Biotechnology (2014): Specialized in DNA aptamers against Coagulation Factor VIII.
  • Pharm.D. (2007): Conducted research on bis(4-nitroaryl-1,4-Dihydropyridine) with pharmacological evaluations.

Professional Experience

  • Assistant Professor: Protein Technology Research Center, Shahid Beheshti University of Medical Science (2014-present).
  • Vice-Chancellor of Research Affairs: Protein Technology Research Center (2018-present).
  • Editorial Roles: Managing Editor for Trends in Peptide and Protein Sciences, Associate Editor for Iranian Journal of Pharmaceutical Research, and Editorial member for Future Natural Products.

Notable Publications

  1. Fathi et al. (2024): Investigated antimicrobial peptides for wound healing, published in Burns (Q2, IF: 3.2).
  2. Fathi et al. (2024): Explored structural features of antimicrobial peptides in Bioorganic Chemistry (Q1, IF: 5.1).
  3. Yazdanicherati et al. (2024): Studied the effect of antimicrobial peptides on gold nanoparticles, published in Modares Journal of Biotechnology.

Teaching Experience

  • Extensive teaching roles in pharmaceutical and medical biotechnology across various institutions, including University of Science and Culture, Gilan University of Medical Sciences, and Shahid Beheshti University of Medical Sciences.

Thesis Supervision

  • Supervised multiple Ph.D. and MSc theses in areas such as biosensors, peptide-nanomolecule interactions, and cancer research.

Conclusion

Dr. Maryam Tabarzad’s impressive academic credentials, significant contributions to pharmaceutical biotechnology, influential editorial roles, and robust teaching and supervisory experience make her a highly suitable candidate for the Best Researcher Award. Her research, particularly in the design and development of antimicrobial peptides and aptamers, along with her leadership in research and education, underscores her excellence in the field.

Publication top notes

Therapeutic applications of nucleic acid aptamers in microbial infections

Aptamers as smart ligands for nano-carriers targeting

Anti-inflammatory activity of bioactive compounds from microalgae and cyanobacteria by focusing on the mechanisms of action

Simultaneous detection of bovine and porcine DNA in pharmaceutical gelatin capsules by duplex PCR assay for Halal authentication

Silymarin antiproliferative and apoptotic effects: insights into its clinical impact in various types of cancer

Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers

Anti-cancer drug delivery using carbohydrate-based polymers

Trends in the design and development of specific aptamers against peptides and proteins

Peptide dendrimers as valuable biomaterials in medical sciences

Nagavendra Kommineni | Pharmacology Award | Best Researcher Award

Posted on by ScienceFather

Dr. Nagavendra Kommineni | Pharmacology Award | Best Researcher Award

Dr. Nagavendra Kommineni, Center for Biomedical Research, Population Council, United States

Dr. Nagavendra Kommineni, Ph.D., is a pharmaceutical scientist specializing in formulation development šŸ§Ŗ. With a background from NIPER-Hyderabad, India, he has expertise in designing innovative drug formulations, particularly in topical and transdermal delivery systems šŸ©ŗ. His work spans nanoparticle-based platforms and sterile manufacturing processes for injectables. Currently a Postdoctoral Research Fellow in New York, he focuses on translational formulations for sexual and reproductive health, including freeze-dried protein formulations and fast-dissolving tablets šŸŒ±. Dr. Kommineni is adept in analytical techniques and actively contributes to GLP and GMP manufacturing standards.

 

Publication Profile

Google Scholar

Education

Dr. Nagavendra Kommineni holds a Ph.D. in Pharmaceutical Sciences from NIPER-Hyderabad, India (2015-2019). He also earned an M.S (Pharm) in Pharmaceutical Sciences (2012-2014) and a Bachelor of Pharmacy degree from Bapatla College of Pharmacy, India (2008-2012).

Work Experience šŸ„

As a Postdoctoral Research Fellow in New York, he pioneers translational formulations for sexual and reproductive health, overseeing formulation development, GLP toxicity studies, and GMP manufacturing. He leads projects on freeze-dried protein formulations and fast-dissolving tablets for HIV and contraception.

 

Research Focus

Dr. Nagavendra Kommineni’s research primarily focuses on advanced drug delivery systems šŸš€, particularly liposomal formulations, nanocarriers, and depot microspheres for targeted therapy. He explores the potential of exosomes and dendrimers in drug delivery, aiming to enhance therapeutic efficacy while minimizing side effects šŸŽÆ. His investigations extend to the development of novel formulations for cancer therapy, psoriasis treatment, and overcoming drug resistance in diseases like breast cancer. Through his work, Dr. Kommineni contributes significantly to the advancement of pharmaceutical science, with a particular emphasis on improving patient outcomes through innovative delivery strategies.

 

Publication Top Notes

šŸ“š Liposomal formulations in clinical use: an updated reviewĀ šŸ” Cited by: 1953 šŸ“… Year: 2017

šŸ“š Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed productsĀ šŸ” Cited by: 228 šŸ“… Year: 2020

šŸ“š Exosomes as naturally occurring vehicles for delivery of biopharmaceuticals: insights from drug delivery to clinical perspectivesšŸ” Cited by: 99 šŸ“… Year: 2021

šŸ“š PLGA/PLA-based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein/peptide deliveryĀ šŸ” Cited by: 94 šŸ“… Year: 2021

šŸ“š Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate canceršŸ” Cited by: 94 šŸ“… Year: 2019

šŸ“š Chitosan: A potential biopolymer in drug delivery and biomedical applications

šŸ“šĀ Lignin: drug/gene delivery and tissue engineering applications

šŸ“š Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy

šŸ“š Microneedle-based natural polysaccharide for drug delivery systems (DDS): progress and challenges

šŸ“š Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model

Alessandra Bitto | Pharmaceutical Science | Most Cited Paper Award

Posted on by ScienceFather

Prof Dr. Alessandra Bitto | Pharmaceutical Science | Most Cited Paper Award

Prof Dr. Alessandra Bitto, University of Messina, Italy

šŸ‘©ā€šŸ”¬ Prof. Alessandra Bitto, born on August 26, 1979, in Messina, Italy, is a distinguished figure in medical research. Graduating with top honors (110/110 cum laude) in Medicine and Surgery from the University of Messina in 2003, her early career was marked by groundbreaking research on neointimal hyperplasia. Dr. Bitto’s contributions have been recognized globally, earning prestigious awards like the Young Researcher Award and the SIF Award for her work on postmenopausal metabolic syndrome. She has presented her findings at international symposiums, notably in Tokyo, Japan, showcasing her expertise on the effects of genistein aglycone. With a penchant for exploration, Dr. Bitto has enriched her knowledge through educational stints across Europe and the USA, delving into diverse fields from molecular biology to neuroscience. Her dedication to advancing medical science is evident in her role as a Visiting Researcher at renowned institutions like the University of Kentucky. Dr. Alessandra Bitto continues to inspire with her passion for research and her commitment to improving global health.

Publication Profile:

Scopus

Orcid

Google Scholar

UNIVERSITY CAREER:

šŸŽ“ Dr. Alessandra Bitto, born and raised in Messina, Italy, embarked on her academic journey by pursuing a degree in Medicine and Surgery at the University of Messina. Throughout her university career, she delved into various disciplines, from human anatomy and physiology to pathology and pharmacology. Her dedication to understanding the intricacies of medical science led her to specialize in pharmacology at the Department of Experimental Clinic of Medicine and Pharmacology. Graduating with top honors in July 2003, her research thesis on the role of MAPK ERK and JNK in neointimal hyperplasia garnered widespread acclaim, laying the foundation for her remarkable contributions to the field.

 

AWARDS AND RECOGNITIONS:

šŸ† Dr. Alessandra Bitto’s contributions to medical science have been widely recognized through numerous awards and accolades. In 2008, she clinched the prestigious Young Researcher Award from the University of Messina, applauding her outstanding scientific productivity. Her groundbreaking research on the effects of phytoestrogen genistein in postmenopausal metabolic syndrome earned her the SIF Award for the best poster at a national seminar in Pharmacology. Invitations as a keynote speaker at international symposiums further highlighted her expertise, notably in Tokyo, Japan. Her excellence was reaffirmed with the Young Investigator Award for her pioneering work on genistein aglycone’s role in managing secondary osteoporosis, culminating in the SIF-Farmindustria Award in 2009. šŸŒŸ

 

EDUCATIONAL EXPERIENCES:

šŸŒ Dr. Alessandra Bitto’s global academic pursuits have enriched her knowledge and expertise in various fields. From delving into histology at the University of Santiago de Compostela, Spain, to exploring molecular biology in Vienna, Austria, her foreign educational experiences have been diverse and extensive. She further broadened her horizons in infectious diseases at Aarhus University, Denmark, and cardiovascular research at the University of Helsinki, Finland. Her journey continued with immersive experiences in molecular genetics at the University of Barcelona, Spain. Notably, she expanded her insights into neurosciences at the Medical University of South Carolina and cardiovascular research at the University of Kentucky in the USA, solidifying her as a globally renowned researcher. šŸŒŸ

 

Research Focus:

šŸ”¬ Dr. Alessandra Bitto’s research focus lies at the intersection of oxidative stress, inflammation, and therapeutic interventions for various health conditions. Her extensive body of work spans across multiple domains, including cardiovascular health, bone metabolism, and wound healing. With a particular emphasis on the effects of phytoestrogens, she has explored their potential in mitigating postmenopausal symptoms and managing metabolic syndrome. Additionally, her studies on erythropoietin’s angiogenic properties and the cholinergic anti-inflammatory pathway highlight her dedication to understanding the mechanisms underlying tissue repair and inflammation modulation. Dr. Bitto’s diverse research endeavors continue to shed light on novel therapeutic strategies for improving human health. šŸ”šŸŒ±

Publication Top Notes:

  1. Oxidative stress: harms and benefits for human health šŸ“š Cited by 3403, 2017
  2. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial šŸ“š Cited by 432, 2007
  3. ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injuryšŸ“š Cited by 409, 2016
  4. Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse šŸ“š Cited by 222, 2004
  5. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study šŸ“š Cited by 221, 2007
  6. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up studyšŸ“š Cited by 217, 2008
  7. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT-and placebo-controlled study. šŸ“š Cited by 210, 2004
  8. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice šŸ“š Cited by 186, 2006
  9. Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in ratsšŸ“š Cited by 184, 2005
  10. Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds šŸ“š Cited by 181, 2006